+7(812) 777-04-88
|
|
|
|
The stability of a drug directly affects the dose a patient receives. The dose received depends on the way the compound is metabolised or accumulated in the body. This metabolism is a key determinant of drug bioavailability. A drug that is rapidly metabolised may require multiple daily dosing or continuous infusion to maintain a concentration in the bloodstream or target organ that is sufficient to elicit a therapeutic effect. However, a slowly metabolised drug may remain in the body for long periods, potentially causing toxic build-up.
Hepatocytes contain enzymes for both phase I (oxidation, reduction and/or hydrolysis of test compound) and phase II (conjugation of test compounds or metabolites) metabolism. |
 |
Dioxin found in eggs from German Farms
(Reuters) - The highly-poisonous chemical dioxin has been discovered in above permitted levels in eggs from two more farms in the central German...
прочитать больше >>
Ghana's Biosafety Law finally receives Presidential Assent
Biosafety Law Prof. Quaye noted was needed to improve the safety of food, improve its yield and ensures its security, hence the law would ensure th...
прочитать больше >>
